Strategic Research
Panacea Biotec Launches Global DENSTAR Initiative to Advance Dengue Vaccine DengiAll® Licensing Across Sub-Saharan Africa
NSE
panaceabio
BSE
531349
Panacea Biotec announced the launch of the DENSTAR project, a four-year international consortium initiative aimed at advancing regulatory approval and broader deployment of its tetravalent live-attenuated dengue vaccine, DengiAll®, in Sub-Saharan Africa. The project is funded under the European Union-supported Global Health EDCTP3 programme and brings together ten partners across nine countries.
PRICE-SENSITIVE TRIGGER
Event: Launch of DENSTAR global dengue vaccine development and licensing programme.
Type: Strategic Research & Development Collaboration
Impact: Positive
Immediate Effect: The initiative strengthens Panacea Biotec’s global vaccine development footprint and could accelerate future international commercialization opportunities for DengiAll® in African markets.
Key Metrics:
- Project Duration: 48 months (starting June 1, 2026)
- Consortium Participants: 10 partners across 9 countries
- EDCTP Contribution: €11.09 million
- Funding Programme: Global Health EDCTP3 Joint Undertaking
- Vaccine Candidate: DengiAll® (Tetravalent Live-Attenuated Dengue Vaccine)
Highlight:
- DENSTAR project has secured €11.09 million funding support under the Global Health EDCTP3 programme backed by the European Union.
What Happened ?
Panacea Biotec announced the launch of the DENSTAR (Dengue Efficacy and Safety Trial in African Region) project to support regulatory approval and wider global access for its dengue vaccine candidate DengiAll®.
The programme aims to advance vaccine licensing in Sub-Saharan Africa through Phase I/III studies in adults and children while generating additional efficacy and immunogenicity data. The project also seeks to evaluate protection against Dengue Virus Serotype-4 (DENV-4) using Controlled Human Infection Models (CHIMs).
The consortium is coordinated by Sclavo Vaccines Association ETS (Italy) and includes leading research institutions, universities and public health organizations from Europe, Africa, Asia and North America.
Key Details
DENSTAR Project Overview:
- Four-year international project commencing June 1, 2026.
- Focused on advancing regulatory approval of DengiAll® in Sub-Saharan Africa.
- Funded under the European Union-supported Global Health EDCTP3 programme.
- Coordinated by Sclavo Vaccines Association ETS, Italy.
- Consortium includes 10 organizations from 9 countries.
- Clinical studies will evaluate vaccine safety and efficacy in African adults and children.
- Project will support broader global access and deployment of DengiAll®.
- Additional research will assess protection against DENV-4 through Controlled Human Infection Models.
- Panacea Biotec serves as the vaccine developer and a key consortium partner.
- Programme supports capacity building, clinical trial readiness and long-term research infrastructure development in Africa.
Note:
- DengiAll® is a tetravalent dengue vaccine targeting all four dengue virus serotypes and is currently in late-stage development. The vaccine is designed as a single-dose formulation suitable for large-scale deployment and technology transfer.
Risk Analysis
Summary:
- While the project enhances scientific and regulatory prospects for DengiAll®, commercialization and licensing outcomes remain dependent on clinical trial results and regulatory approvals.
Key Risks:
- Regulatory approvals in multiple jurisdictions remain pending.
- Clinical efficacy and safety outcomes must meet predefined study endpoints.
- Vaccine adoption timelines may vary across participating African countries.
- Long-term commercial benefits depend on successful licensing and deployment.
- Public health programme funding and procurement decisions may influence market penetration.
Worst Case Scenario:
- If clinical trials fail to achieve required efficacy or safety outcomes, regulatory approvals and future commercialization opportunities for DengiAll® in target markets could be delayed or curtailed.
Risk Level: Medium
Company Commentary
- DENSTAR aims to facilitate broader use of DengiAll® in Africa and globally.
- The consortium represents a public-private partnership involving global vaccine and public health experts.
- DengiAll® is designed as a practical, scalable and cost-effective dengue prevention solution.
- The project seeks to reduce dengue disease burden and improve public health outcomes in developing regions.
- Panacea Biotec believes the initiative can create long-term global health impact beyond the project duration.
Official Exchange Filing: Panacea Biotec Limited